Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) | RFA CA 21 001

Opportunity Information: Apply for RFA CA 21 001

The Small Business Transition Grant for Early Career Scientists (R42, Clinical Trial Not Allowed), announced by the National Institutes of Health (NIH) under funding opportunity number RFA-CA-21-001, is a discretionary grant opportunity designed to help move promising discoveries out of academic labs and into small businesses. Its central focus is on early-career academic scientists who want to shift toward entrepreneurship, while also speeding up the transfer of technologies that originate in university research settings into U.S.-based small companies that can further develop them into useful products. In practical terms, the program sits at the intersection of academic innovation and commercialization, aiming to turn research outputs into real-world technologies that can ultimately benefit public health.

The NIH frames the opportunity around a common gap that appears during commercialization. Universities are excellent at generating discoveries and early prototypes, while small businesses often have the operational focus, product development experience, and commercialization mindset needed to push a technology toward a deployable product. However, when an invention is ready to leave the academic environment, two obstacles often slow things down: first, assembling the right team with the skills to lead the technology within a small business context, and second, securing early-stage funding to mature the technology to a point where it is credible for later investment, partnerships, or additional non-dilutive funding. This grant is structured to address both issues at once, making entrepreneurial mentoring and product development support equally important goals rather than treating mentoring as an optional add-on.

The mechanism is an R42 award, which is commonly associated with the Small Business Technology Transfer (STTR) program structure, where a small business is the applicant organization and collaboration with a research institution is typically part of the development pathway. The opportunity emphasizes technology development in small businesses supported through NIH small business programs, while explicitly targeting the transition of early-career scientists into entrepreneurial roles. In other words, the grant is not only meant to advance a specific technology but also to help create a capable founder or scientific entrepreneur who can operate effectively in a small business setting, supported by structured guidance and mentoring.

A key limitation is that clinical trials are not allowed under this FOA. That generally means funded work should focus on preclinical development, validation, feasibility studies, prototype refinement, testing, and other activities that move a technology forward without initiating a clinical trial as defined by NIH policy. Applicants typically need to shape their aims around product-oriented development milestones that are appropriate for early commercialization stages while staying within the non-clinical-trial boundary.

Eligibility is centered on small businesses, with the listing specifying small businesses as eligible applicants. The announcement also states clear restrictions on foreign participation: non-U.S. (non-domestic) entities, including foreign institutions, are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. At the same time, it notes that foreign components, as NIH defines them in the NIH Grants Policy Statement, may be allowed in some circumstances, which usually means limited, well-justified elements of the project could occur outside the U.S. if they are essential and permitted under NIH policy. Applicants are directed to the full funding announcement for the detailed eligibility rules and definitions.

From an administrative standpoint, the opportunity is offered by the NIH, falls under activity categories related to education and health, and is associated with CFDA numbers 93.172 and 93.394. The original closing date listed is March 24, 2021, and the announcement was created on November 25, 2020. The summary information provided does not specify an award ceiling or the expected number of awards in the excerpt, so those details would normally be confirmed in the full FOA text and any linked budget guidelines.

Overall, this FOA is best understood as a targeted bridge from academia to entrepreneurship: it supports an early-career scientist stepping into a small business role while simultaneously providing resources to advance an academic-origin technology toward a product-ready state. It is explicitly built to strengthen the human side of commercialization (mentorship and entrepreneurial development) and the technical side (early-stage product development), with the intent of increasing the odds that strong academic innovations successfully become viable small business technologies.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172, 93.394.
• This funding opportunity was created on 2020-11-25.
• Applicants must submit their applications by 2021-03-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA CA 21 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: